RCT: Intramuscular AZD7442 (Tixagevimab–Cilgavimab) for prevention of Covid-19.
21 Apr, 2022 | 10:29h | UTC
Commentary on Twitter
AZD7442 (tixagevimab/cilgavimab) found to have about 76% efficacy in preventing symptomatic Covid-19 infection. https://t.co/8tmvz3xI4I pic.twitter.com/fOegZjBRA6
— NEJM (@NEJM) April 20, 2022